Conclusion
KRAS-mutant non-small cell lung cancer
The combination of B + HCQ in second- or later-line treatment of patients with advanced This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine in patients with advanced KRAS-mutant non-small cell lung cancer.